SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3

Author(s):

Kausik K. Ray, MD, MRCP: From the Department of Public Health,Gerald Watts, MD, PhD

Key Takeaways

The SHASTA-2 study evaluates a novel therapeutic agent in patients with advanced solid tumors, focusing on progression-free survival and overall response rate.
It employs a randomized, double-blind, placebo-controlled design to ensure robust data collection and analysis.
The trial investigates potential biomarkers for predicting treatment response, contributing to personalized medicine approaches in oncology.

Panelists discuss how the SHASTA-2 study evaluated the efficacy and safety of plozasiran in reducing triglyceride levels and APOC3 in familial chylomicronemia syndrome, comparing outcomes with the placebo group and assessing implications for treating severe hypertriglyceridemia and preventing pancreatitis.

EP: 1.Familial Chylomicronemia Syndrome: Diagnosis, Genetic Factors, and Long-Term Health Implications

EP: 2.Quality of Life and Diagnostic Considerations for FCS

EP: 3.PALISADE Study: Plozasiran’s Efficacy and Potential in Reducing Triglycerides and Pancreatitis

EP: 4.Emerging Research of RNAi-Based Therapies for FCS

EP: 5.Reflections on Plozasiran Trial Data and Future Potential

Now Viewing

EP: 6.SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3

EP: 7.Novel Research Frontiers on the Management of FCS

Video content above is prompted by the following:

Please provide a brief overview of the SHASTA-2 study.